

Panacea Biotech receives \$24.32 M award from U.N. Agencies

December 23, 2019 | News

Easyfive-TT (DTwP-HepB-Hib) was introduced by Panacea Biotech as world's first fully liquid wP-based pentavalent vaccine in Indian market in 2005.



Panacea Biotech, one of the India's leading Biotechnology Company received Awards worth **\$24.32 Million** (Over Rs.170 crores) from U.N. Agencies (UNICEF and PAHO) for supply of its Easyfive-TT, a fully liquid WHO prequalified Pentavalent Vaccine. UNICEF award is for year 2020 and award of PAHO is for three (3) years i.e. 2020-2022.

Pediatric vaccination plays an important role to achieve Sustainable Development Goals set by the United Nations, in particular the target to reduce under-five mortality rate to less than 25 per 1000 live births. Pentavalent vaccine protects children against five deadly diseases; Diphtheria, Tetanus, Pertussis, Hepatitis B and invasive infections caused by Haemophilus Influenza Type b – becoming the foundation of paediatric immunization programs across the world.

Easyfive-TT (DTwP-HepB-Hib) was introduced by Panacea Biotech as world's first fully liquid wP-based pentavalent vaccine in Indian market in 2005. With WHO prequalification in 2008, over 100 million doses have been supplied to more than 50 countries globally. Easyfive-TT is ready for use without further preparation by healthcare workers in the field, which offers major healthcare advantages in countries with challenging infrastructure and hygiene problems.

Panacea Biotech has contributed significantly for Children's Health and has partnered with WHO, UNICEF & PAHO in their efforts to maximize coverage of vaccines under the Expanded Program on Immunization (EPI) in developing countries. The Company has pioneered in development of wP based fully-liquid combination vaccines and has launched: **Ecovac** (Diphtheria, Wholecell Pertussis, Tetanus, Hepatitis B), **Easyfour** (Diphtheria, Wholecell Pertussis, Tetanus and Hib), **Easyfive-TT** (Diphtheria, Whole cell Pertussis, Tetanus, Hepatitis B and Hib), **Easysix** (Diphtheria, Whole cell Pertussis, Tetanus, Hepatitis B, Hib and IPV) – the world's first and only wP-IPV hexavalent vaccine) to meet to programmatic needs of evolving immunization programs. As a responsible and reliable partner, Panacea Biotech thus contributes to the success of the Global Alliance for Vaccines and Immunization (GAVI Alliance) in accelerating access to these vaccines across the globe.

Dr. Rajesh Jain, Managing Director, commented, "I have always believed that innovation delivers sustainable business value and we are glad to witness the same once again. We are re-building on our deep-rooted foundation in biological business and would like to congratulate all our team members, employees, shareholders and other stakeholders. We look forward with confidence and conviction about our performance year after year."